

# ANIKA THERAPEUTICS, INC.

## Second Quarter 2015 Business Update

July 30, 2015



# SAFE HARBOR STATEMENT

*The statements made in this presentation that are not statements of historical fact are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties, and other factors. The words “potential,” “develop,” “promising,” “believe,” “will,” “would,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “likely,” and other expressions, which are predictions of, or indicate future events and trends, and which do not constitute historical matters, identify forward-looking statements, including without limitation, management’s discussion of the company’s growth and strategic plans. The Company’s actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including the results of its research and development efforts and timing of regulatory approvals.*

# SOLID Q2 2015: PROGRESS ON ALL FRONTS

## Robust End-User Demand

ORTHOVISC Leads  
Multi-Injection  
Market

MONOVISC is #2 in  
Single-Injection  
Market

## Growing Financial Strength

\$22.9M Revenue

\$7.8M Net Income

\$0.51 Diluted EPS

## Steady Pipeline Progress


IDE Filed/Approved  
for MONOVISC

IDE Approved for  
HYALOFAST

Ongoing Progress on  
CINGAL

# ORTHOVISC & MONOVISC: EXPANDING REACH


**Gains in U.S.  
Visco Market**



**ORTHOVISC & MONOVISC  
Combined Share of 26%**

**International  
Traction**

**New Distribution  
Agreements Signed  
for MONOVISC**



**New  
Indication**

**IDE for Hip OA Pain  
Submitted/Approved  
for MONOVISC**

# PIPELINE ADVANCEMENT: SETTING THE FUTURE

## CINGAL

- Poised to be First Viscosupplement to Combine HA Formulation with a Well-Established Steroid
- 13-02 Study Demonstrates Excellent Safety Profile
- In Regulatory Process in U.S., Europe, and Canada

## HYALOFAST

- Biodegradable 3D Scaffold that Enables and Promotes Cartilage Regeneration
- IDE Approved by FDA
- Patient Enrollment to Commence in Q4

## Research Collaboration

- Partnership with UMass Amherst to Develop Novel Treatment for Rheumatoid Arthritis
- Combines Anika's HA technology with UMass Amherst's preclinical research and scientific expertise

# SOLID FINANCIAL RESULTS IN Q2 2015



Product  
Revenue  
8%

- End-User Demand Driving Growth
- Mitek Inventory Adjustment to Complete in Q3

---

38<sup>th</sup> Quarter

of YoY growth  
for ORTHOVISC

4<sup>th</sup> Quarter

of consecutive growth  
for MONOVISC

---

Excluding impact of Q2 FY14  
\$5M Milestone Payment. . .



Net  
Income  
\$1.6M



Diluted  
EPS  
\$0.11

# Q&A

## Anika Therapeutics, Inc. Second Quarter 2015 Business Update

July 30, 2015

